CIK 0001177648 · Non-accelerated filer<br>Smaller reporting company
ENANTA PHARMACEUTICALS INC
Sign in to watch- Ticker
- ENTA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Entity type
- operating
- EIN
- 043205099
- Phone
- 617 607 0800
- Business address
- 4 KINGSBURY AVENUE, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-01 | Luly Jay R. President and CEO | Shares withheld for taxes | −3,829 | $8.60 | $33K | 806,780 |
| 2024-11-27 | Kowalsky Matthew Paul Chief Legal Officer | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2024-11-27 | Luu Brendan Chief Business Officer | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2024-11-27 | Kieffer Tara Lynn Chief Product Strategy Officer | Grant or award · Stock Option (right to buy) | +81,000 | 81,000 | ||
| 2024-11-27 | Rottinghaus Scott T. Chief Medical Officer | Grant or award · Stock Option (right to buy) | +87,000 | 87,000 | ||
| 2024-11-27 | Or Yat Sun Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +87,000 | 87,000 | ||
| 2024-11-27 | MELLETT PAUL J Chief Fin. & Admin Officer | Grant or award · Stock Option (right to buy) | +81,000 | 81,000 | ||
| 2024-11-27 | Luly Jay R. President and CEO | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-08-08 | Rottinghaus Scott T. Chief Medical Officer | Shares withheld for taxes | −1,466 | $12.73 | $19K | 18,784 |
| 2024-07-15 | Rottinghaus Scott T. Chief Medical Officer | Option exercise 10b5-1 | +5,375 | $8.99 | $48K | 27,092 |
| 2024-07-15 | Rottinghaus Scott T. Chief Medical Officer | Sale 10b5-1 | −5,375 | $17.08 | $92K | 21,717 |
| 2024-07-15 | Rottinghaus Scott T. Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,375 | 80,625 | ||
| 2024-07-12 | Rottinghaus Scott T. Chief Medical Officer | Sale 10b5-1 | −2,271 | $15.04 | $34K | 21,717 |
| 2024-07-11 | Rottinghaus Scott T. Chief Medical Officer | Sale 10b5-1 | −4,299 | $15.07 | $65K | 23,988 |
| 2024-06-17 | Kieffer Tara Lynn Chief Product Strategy Officer | Sale 10b5-1 | −7,266 | $12.33 | $90K | 32,341 |
| 2024-04-29 | Kowalsky Matthew Paul Chief Legal Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2024-03-06 | Vance Terry Director | Grant or award · Stock Option (right to buy) | +15,700 | 15,700 | ||
| 2024-03-06 | Russell Lesley Director | Grant or award · Stock Option (right to buy) | +15,700 | 15,700 | ||
| 2024-03-06 | Peterson Kristine Director | Grant or award · Stock Option (right to buy) | +15,700 | 15,700 | ||
| 2024-03-06 | Hata Yujiro S Director | Grant or award · Stock Option (right to buy) | +15,700 | 15,700 |
Page 5 of 7 · 135 trades